Supernus Announces Third Quarter 2026 Financial Results

Supernus posts strong Q3 growth and prepares for imminent Indivior merger.

What the company is saying

Supernus Pharmaceuticals highlights a 29% year-to-date revenue growth, attributing momentum to its commercial portfolio, especially growth products. CEO Jack Khattar frames the narrative around operational execution and the transformative impact of the pending Indivior merger, which is set to close within days and promises $125 million in annual cost synergies. The company emphasizes ONAPGO's $17.1 million in Q3 sales, 17% prescription growth over Q2, and seven-year FDA orphan-drug exclusivity. ZURZUVAE collaboration revenue reached $41.7 million, reflecting 53% U.S. sales growth and 43% prescription growth year-over-year. Qelbree net sales rose 12% to $90.8 million with 282,887 prescriptions, up 18%, and GOCOVRI achieved record net sales of $42.6 million. Pipeline updates include ongoing Phase 2b studies for SPN-817 and SPN-820, and a planned Phase 1 for SPN-443 by year-end 2026. The company raises full-year 2026 guidance for revenues and adjusted operating earnings, but notes this will be superseded by combined company reporting post-merger. The tone is confident, data-driven, and forward-looking, with clear explanations that higher revenues and lower SG&A drove improved earnings.

What the data suggests

The disclosed figures show Supernus delivered $226.8 million in Q3 2026 total revenues, up 18% from $192.1 million in Q3 2025. Net product sales were $178.6 million, with Qelbree contributing $90.8 million, GOCOVRI $42.6 million, and ONAPGO $17.1 million. Collaboration revenue from ZURZUVAE was $41.7 million, representing 50% of Biogen's net revenues for the product. Prescription growth was robust: ONAPGO up 17% sequentially, ZURZUVAE up 43% year-over-year, and Qelbree up 18% with adult and pediatric segments growing 25% and 16%. Operating earnings swung from a $45.1 million loss in Q3 2025 to a $21.2 million profit in Q3 2026, while adjusted operating earnings rose to $55.2 million from $41.9 million. Net earnings were $20.9 million with diluted EPS of $0.35. Cash and equivalents increased to $359.5 million from $308.7 million at year-end 2025. The company raised 2026 guidance to $875–$900 million in revenues and $160–$180 million in adjusted operating earnings. The merger with Indivior, approved by shareholders and closing imminently, is expected to deliver $125 million in annual cost synergies, but this figure is a projection without a detailed breakdown. The data is comprehensive, period-over-period comparisons are clear, and management attributes improved results to higher revenues and lower acquisition-related costs.

Analysis

The announcement's tone is positive but proportionate to the substantial realised progress disclosed. The majority of key claims are supported by concrete, period-over-period financial and operational data, including revenue, operating earnings, net income, and cash balances. Forward-looking statements (such as merger synergies and regulatory timelines) are clearly separated from realised results and do not dominate the narrative. The merger with Indivior is imminent (closing expected within days), and the $125 million synergy target, while forward-looking, is presented as an expectation rather than a realised fact. There is no evidence of exaggerated language or narrative inflation; the release is data-rich and transparent. No large capital outlay is disclosed without a clear, near-term benefit, and the company provides both GAAP and non-GAAP profitability metrics alongside revenue growth.

Risk flags

• ●Merger integration risk is significant, as the $125 million in annual cost synergies is an unproven projection and successful realization depends on effective operational and cultural integration of Supernus and Indivior. Failure to achieve these synergies could undermine the merger's value proposition.
• ●Revenue guidance and financial outlook will become obsolete immediately after the merger closes, introducing uncertainty about the combined company's future performance and reporting structure. Investors will need to reassess expectations once new guidance is issued.
• ●Pipeline execution risk remains, as key assets like SPN-817 and SPN-820 are still in Phase 2b trials and SPN-443 has yet to enter Phase 1. Delays or negative trial outcomes could impact future growth.
• ●Product concentration risk persists, with Qelbree, ZURZUVAE, and GOCOVRI accounting for the majority of revenue growth. Any market or regulatory setbacks for these products could materially affect financial results.
• ●Forward-looking claims about cost synergies and strategic positioning are not yet substantiated by realised results, and no detailed breakdown of synergy sources is provided. This leaves room for execution shortfalls or overestimated benefits.

Bottom line

Supernus delivered strong Q3 2026 results, with double-digit revenue and prescription growth across key products and a swing to positive operating earnings. The imminent merger with Indivior, already approved by shareholders and set to close within days, will fundamentally reshape the company's scale and reporting, with $125 million in annual cost synergies projected but not yet realised. The company's raised 2026 guidance is now a short-term reference point, as new combined company forecasts will be needed post-merger. While the financial disclosures are comprehensive and the growth story is credible, investors should focus on the execution of merger integration, realisation of projected synergies, and the continued progress of the product pipeline. The most important takeaway is that Supernus is transitioning from a standalone growth story to a larger, more complex CNS biopharma platform, and the next set of disclosures will be critical for assessing the success of this transformation.

Announcement summary

(NASDAQ:SUPN) Supernus Pharmaceuticals, Inc. announced its financial results for the third quarter of 2026 and provided updates on company developments. ONAPGO net product sales were $17.1 million in Q3 2026, with over 400 enrollment forms submitted and prescriptions growing by 17% compared to Q2 2026. The FDA has granted ONAPGO seven years of orphan-drug exclusivity for treating motor fluctuations in adults with advanced Parkinson’s disease, and a supplemental New Drug Application for a second supplier has been submitted, with potential FDA approval by mid-2027. Collaboration revenue from ZURZUVAE was $41.7 million in Q3 2026, representing 50% of net revenues recorded by Biogen Inc.; U.S. sales of ZURZUVAE increased approximately 53% year-over-year, and prescriptions rose by 43%. Net sales of Qelbree increased 12% to $90.8 million in Q3 2026, with 282,887 IQVIA prescriptions, up 18% year-over-year; adult and pediatric prescription growth was 25% and 16%, respectively. GOCOVRI net sales grew by 4% to an all-time high of $42.6 million in Q3 2026, with a 4% increase in prescriptions. The SPN-817 Phase 2b study is ongoing with a targeted enrollment of approximately 258 adult patients with treatment-resistant focal seizures. The SPN-820 Phase 2b trial is enrolling approximately 200 adults with major depressive disorder to assess safety, tolerability, and rapid onset of improvement. The company expects to initiate a Phase 1 study for SPN-443 in adult healthy volunteers by the end of 2026. On August 3, 2026, Supernus announced an all-stock merger agreement with Indivior Pharmaceuticals, Inc., approved by shareholders on October 15, 2026, and expected to close on November 2, 2026; the combined company will be named Supernus, Inc., listed on Nasdaq under 'SUPN' from November 3, 2026, and is expected to realize $125 million in annual cost synergies. For Q3 2026, total net product sales were $178.6 million, collaboration revenue (ZURZUVAE) was $41.7 million, and total revenues were $226.8 million, up 18% from $192.1 million in Q3 2025. Operating earnings were $21.2 million for Q3 2026, compared to a loss of $45.1 million in Q3 2025. Adjusted operating earnings (non-GAAP) were $55.2 million for Q3 2026, up from $41.9 million in Q3 2025. Net earnings and diluted earnings per share for Q3 2026 were $20.9 million and $0.35, respectively. Cash, cash equivalents, and current marketable securities were approximately $359.5 million as of September 30, 2026, compared to $308.7 million as of December 31, 2025. The company raised its full-year 2026 guidance, with total revenues expected between $875 million and $900 million, ONAPGO net sales of $60 million to $65 million, Trokendi XR and Oxtellar XR net sales of $60 million to $67 million, GAAP operating earnings (loss) of $(5) million to $(40) million, and adjusted operating earnings (non-GAAP) of $160 million to $180 million. The guidance will no longer apply if the merger closes as planned on November 2, 2026.

Disagree with this article?